

Oncology Test Request Form

Client Information (required) Client Name Client Account No. Client Phone Client Order No. Address City State Zip Code Submitting Provider/Provider Name Information (required) Submitting/Referring Provider (Last, First) Fill in only if Call Back is required. Phone (Provider's National I.D. (NPI) *Fax number given must be from a fax machine that complies with applicable HIPAA regulation. Pathologist's Name (required) Submitting/Referring Pathologist (Last, First) ☐ Yes ☐ No Phone (Has specimen been fixed in 10% neutral buffered formalin for 6 to 72 hours? *Fax number given must be from a fax machine that complies with applicable HIPAA regulation. **New York State Patients: Informed Consent for Genetic Testing** "I hereby confirm that informed consent has been signed by an individual legally authorized to do so and is on file with this office or the individual's provider's office." Signature _ Note: It is the client's responsibility to maintain documentation of the order. MCL Internal Use Only

Patient Information (required)

Patient ID (Medical Record No.)			
Patient Name (Last, First, Middle)			
Gender □ Male □ Female	Birth Date (Month DD, YYYY)		
Collection Date (Month DD, YYYY)	Time □ a.m. □ p.m.		

Specimens Provided (required)

☐ Blood	☐ Paraffin block	☐ Tissue
☐ Bone Marrow	No. sent:	No. sent:
☐ Fixed Cells	Indicate source:	☐ Frozen
☐ Cultured Cells		☐ Fixed Formalin
□ DNA		☐ Wet Tissue
☐ Lymph Node	☐ Slides	☐ Other Fixative
☐ Spleen	No. sent:	type:
		□ Other
		Anatomic site:
CBC results:		
HB	RBC	WBC
HCT	MCV	PLT
If ordering HER2 1	testing:	
Was specimen fixed in 10	% neutral buffered formalin wit	hin 1 hour from surgical collection time?

Pathology/Clinical Diagnosis (required)

3,		V 1 7	
(Include a brief history, pertinent lab and reason for referral.)	oratory results	s, suspected diagnosis,	
ICD-10 Diagnosis Code			

- · An itemized invoice will be sent each month.
- · Payment terms are net 30 days.

Call the Business Office with billing related questions: 800-447-6424 (US and Canada) 507-266-5490 (outside the US)

Visit www.MayoClinicLabs.com for the most up-to-date test and shipping information.

Mayo Clinic Laboratories

3050 Superior Drive NW

Rochester, MN 55901

Customer Service: 855-516-8404

Ship specimens to:

Patient Information (required)

Patient ID (Medical Record No.)	Client Account No.
Patient Name (Last, First, Middle)	Client Order No.
Birth Date (Month DD, YYYY)	

FEATURED ONCOLOGY TESTING

PD-L1 Immunohistochemical stains			
□ PDL1	PD-L1 (SP263), Semi-Quantitative Immunohistochemistry, Manual		
□ PDL1S	PD-L1 (SP142), Semi-Quantitative Immunohistochemistry, Manual		
□ PDL12	PD-L1 (22C3), Semi-Quantitative Immunohistochemistry, Manual		
Microsatellite Instability (MSI)/Mismatch Repair			
☐ MSIHC	Microsatellite Instability (MSI)/ Immunohistochemistry (IHC) Profile-Lynch/ Hereditary Nonpolyposis Colorectal Cancer (HNPCC) Screen		
□ MSI	Microsatellite Instability (MSI), Tumor		
□ IHC	Mismatch Repair (MMR) Protein Immunohistochemistry Only, Tumor		

Chromoson	ne Analysis
☐ CHRBF	Chromosome Analysis, Body Fluid
☐ CHRST	Chromosome Analysis, Solid Tumors
Next-Gener	ration Sequencing (NGS) Panels
☐ GISTP	GIST-Targeted Gene Panel by Next- Generation Sequencing, Tumor
□ LNGPR	Lung Cancer-Targeted Gene Panel with Rearrangement, Tumor (mutations and rearrangements)
☐ MELP	Melanoma Targeted Gene Panel by Next- Generation Sequencing, Tumor
□ NONCP	Neuro-Oncology Expanded Panel with Rearragement, Tumor
□ RASFP	RAS/RAF Targeted Gene Panel by Next- Generation Sequencing, Tumor
□ CAPN	Solid Tumor Targeted Cancer Gene Panel by Next-Generation Sequencing

Chromosomal Microarray		
□ CMAPT	Chromosomal Microarray, Tumor, Formalin- Fixed Paraffin-Embedded	
☐ CMAT	Chromosomal Microarray, Tumor, Fresh or Frozen using Affymetrix Cytoscan HD	
Cell-Free DNA (cfDNA) Testing		
□ BRAFB	Cell-Free DNA BRAF V600 Test, Blood	
□ EGFRD	Cell-Free DNA EGFR Exon 18, 19, 20, 21, Mutation Analysis, Blood	
□ T790M	Cell-Free DNA EGFR T790M Mutation Analysis, Blood	
☐ KRASD	Cell-Free DNA KRAS 12, 13, 61, 146, Blood	

PATHOLOG	Y	
□ PATHC	Pathology Consultation Appropriate stains and ancillary testing may be performed in order to render an accurate diagnosis	
MATE PAIR SEQUENCING		
☐ MTRTI	MatePair, Targeted Rearrangements, Oncology	
PATHOLOGY: TARGETED TUMOR TESTING		
Bone and Soft Tissue		
□ F0X0F	Alveolar Rhabdomyosarcoma (ARMS),	

PATHULUG	Y: TARGETED TUMUR TESTING	
Bone and Soft Tissue		
□ F0X0F	Alveolar Rhabdomyosarcoma (ARMS), 13q14 (FOXO1 or FKHR) Rearrangement, FISH, Tissue	
□ ETV6F	ETV6 (12p13.2) Rearrangement, FISH, Tissue	
□ ARMS	Alveolar Rhabdomyosarcoma by Reverse Transcriptase PCR (RT-PCR)	
□ TFE3F	Alveolar Soft Part Sarcoma (ASPS)/Renal Cell Carcinoma (RCC), Xp11.23 (TFE3), FISH, Tissue	
□ MASF	Angiosarcoma, MYC (8q24) Amplification, FISH, Tissue	
☐ CTNNB	Beta-Catenin (CTNNB1) Mutation Analysis, Tumor	
□ DSRCT	Desmoplastic Small Round-Cell Tumor by Reverse Transcriptase PCR (RT-PCR)	
□ ESTUF	Endometrial Stromal Tumors (EST), 7p15 (JAZF1), 6p21.32 (PHF1), 17p13.3 (YWHAE) Rearrangement, FISH, Tissue	
□ EWSF	Ewing Sarcoma (EWS), 22q12 (EWSR1)	

Rearrangement, FISH, Tissue

□ EWS	Ewing Sarcoma, by Reverse Transcriptase PCR (RT-PCR)
□ IMTF	Inflammatory Myofibroblastic Tumors (IMT), 2p23 (ALK) Rearrangement, FISH, Tissue
☐ KIT8	KIT Exon 8, Mutation Analysis
□ КІТ9	KIT Exon 9, Mutation Analysis
☐ KIT11	KIT Exon 11, Mutation Analysis
☐ KIT13	KIT Exon 13, Mutation Analysis
☐ KIT17	KIT Exon 17, Mutation Analysis
□ FUSF	Low-Grade Fibromyxoid Sarcoma (LGFMS) 16p11.2 (FUS or TLS) Rearrangement, FISH, Tissue
□ MDM2F	MDM2 (12q15) Amplification, Well- Differentiated Liposarcoma/Atypical Lipomatous Tumor, FISH, Tissue
□ DDITF	Myxoid/Round Cell Liposarcoma, 12q13 (DDIT3 or CHOP) Rearrangement, FISH, Tissue
□ MYCNF	Neuroblastoma, 2p24 (MYCN) Amplification, FISH
□ PDG12	PDGFRA Exon 12, Mutation Analysis
□ PDG14	PDGFRA Exon 14, Mutation Analysis
□ PDG18	PDGFRA Exon 18, Mutation Analysis
□ PDGF	PDGFB (22q13), Dermatofibrosarcoma Protuberans/Giant Cell Fibroblastoma, FISH, Tissue
□ SS18F	Synovial Sarcoma (SS), 18q11.2 (SS18 or SYT) Rearrangement, FISH, Tissue
□ SYT	Synovial Sarcoma by Reverse Transcriptase PCR (RT-PCR)

Breast	
□ MASF	Angiosarcoma, MYC (8q24) Amplification, FISH, Tissue
□ СТСВС	Circulating Tumor Cells (CTC) for Breast Cancer by CellSearch, Blood
☐ FGF1F	FGFR1 (8p11.2) Amplification, FISH, Tissue
☐ HER2F	HER2 Amplification Associated with Breast Cancer, FISH, Tissue
□ ESR1	Estrogen Receptor 1 (ESR1) Mutation Analysis, Tumor
□ ETV6F	ETV6 (12p13.2) Rearrangement, FISH, Tissue
	ochemical assays interpreted image analysis
□ ERPR	Estrogen/Progesterone Receptor, Semi- Quantitative, Manual
☐ KI67B	Ki-67(MIB-1), Breast, Quantitative, Automated
□ HERBA	Breast, Quantitative, Automated with HER2 FISH reflex
☐ HERBN	HER2, Breast, Quantitative, Automated, No Reflex
□ HERDM	HER2, Breast, DCIS, Quantitative, Manual with HER2 FISH Reflex
☐ HERDN	HER2, Breast, DCIS, Quantitative, Manual

USP6 (17p13), Aneurysmal Bone Cyst and

□ USPF

Patient Information (required)

Account No.
Order No.

Patient Na	une (last, first, middie)			Client Order No.		
Birth Date	(Month DD, YYYY)					
Gastrointe	etinal	☐ FUROC	UroVvsion for	Detection of Bladder Cancer,	Neuro-ond	rology
□ BILAO	Biliary Tract Malignancy, FISH	101100	Urine	Botootion of Biaddor Garicon,	□ GLIOF	1p/19q Deletion in Gliomas, FISH, Tissue
□ BRAFT	BRAF Mutation Analysis (V600E), Tumor	□ NUT1F	٠.	14) Rearrangement, FISH,	□ BRAFT	BRAF Mutation Analysis (V600E), Tumor
□ стссс	Circulating Tumor Cells (CTC) for Colorectal	□ PR0F	Tissue Prostate Tum	or, FISH, Tissue	□ CMAPT	Chromosomal Microarray, Tumor, Formalin-
□ EGFRT	Cancer by CellSearch, Blood EGFR Gene, Mutation Analysis, 29 Mutation	□ TFEBF		rcinoma, 6p21.1 (TFEB) ent, FISH, Tissue	□ GCTF	Fixed Paraffin-Embedded Germ Cell Tumor (GCT), Isochromosome 12p,
□ PRKAF	Panel, Tumor Fibrolamellar Carcinoma, 19p13.1 (PRKACA)	Gynecology		□ IDH12	FISH, Tissue IDH12 Isocitrate Dehydrogenase 1 and 2	
	Rearrangement, FISH, Tissue	Endometria	I/Uterine Carc	inoma		(IDH1/IDH2) Mutation Analysis, Tumor
☐ FGFR2	FGFR2 (10q26.1) Rearrangement, FISH, Tissue	☐ ESTUF		Stromal Tumors (EST), 7p15	□ MEDF	Medulloblastoma, FISH, Tissue
☐ GISTP	GIST-Targeted Gene Panel by Next-			1.32 (PHF1), 17p13.3 (YWHAE) ent, FISH, Tissue	☐ MGMT	MGMT Promoter Methylation, Tumor
	Generation Sequencing, Tumor	☐ ML1HM	•	methylation Analysis, Tumor	□ NONCP	Neuro-Oncology Expanded Panel with Rearrangement, Tumor
☐ H2GEF	HER2 Amplification Associated with Gastroesophageal Cancer, FISH, Tissue	0			☐ TERT	TERT Promoter Analysis, Tumor
□ HERGM	HER2, Gastric/Esophageal, Semi-	□ XL2	FOXL2 Mutat	tion Analysis, Tumor	Pulmonary	
	Quantitative Immunohistochemistry,	Gestational	/Trophoblatic	Disease/ Molar Pregnancy	□ BRAFT	BRAF Mutation Analysis (V600E), Tumor
☐ HERGN	Manual HER2, Gastric/Esophageal, Semi-	□ POCF		Conception (POC) Aneuploidy	□ EGFRT	EGFR Gene, Mutation Analysis, 29 Mutation Panel, Tumor
	Quantitative Immunohistochemistry, Manual, No Reflex	Lower Anal	Detection, FISH, Paraffin-Embedded Tissue		☐ FALKC	ALK on Cytology Specimens, FISH
☐ KINET	Ki-67(MIB-1), Gastrointestinal/Pancreatic			Genital Tract Carcinoma		FGFR1 (8p11.2) Amplification, FISH, Tissue
KINLI	Neuroendocrine Tumors, Quantitative Immunohistochemistry, Automated	☐ HPVE6	E7, RNA In Si	lomavirus (HPV) High-Risk E6/	☐ KRASO	KRAS Mutation Analysis, 7 Mutation Panel, Other (Non-Colorectal)
☐ KIT8	KIT Exon 8, Mutation Analysis	☐ HPVHL		lomavirus (HPV) High/Low Situ Hybridization	□ LCAF	Lung Cancer, ALK (2p23) Rearrangement,
□ КІТ9	KIT Exon 9, Mutation Analysis	☐ HPVHR	-	lomavirus (HPV), High-Risk,		FISH, Tissue
☐ KIT11	KIT Exon 11, Mutation Analysis		DNA In Situ H	•	□ EGFRR	Lung Cancer, EGFR with ALK Reflex, Tumor Lung Cancer-Targeted Gene Panel with
☐ KIT13	KIT Exon 13, Mutation Analysis KIT Exon 17, Mutation Analysis	☐ HPVLR	Human Papill DNA In Situ F	lomavirus (HPV), Low-Risk, Hybridization	□ LNGPR	Rearrangement, Tumor (mutations and rearrangements)
□ KRASC	KRAS Mutation Analysis, 7 Mutation Panel,	Head and	Head and Neck		□ LUNGP	Lung Cancer-Targeted Gene Panel, Tumor
11111100	Colorectal	☐ FGF1F			Lower	(mutations only)
□ METF	MET (7q31), FISH, Tissue	☐ HPVHL		lomavirus (HPV) High/Low Situ Hybridization	□ LUNGR	Lung Cancer Rearrangement Testing, Tumor (rearrangements only)
☐ ML1HM ☐ BRMLH	MLH1 Hypermethylation Analysis, Tumor MLH1 Hypermethylation and BRAF	☐ HPVHR	•	lomavirus (HPV), High-Risk,	□ RETF	Lung Cancer, RET (10q11) Rearrangement,
	Mutation Analysis, Tumor		DNA In Situ H	lybridization	□ ROS1F	FISH, Tissue Lung Cancer, ROS1 (6q22) Rearrangement,
☐ MSIHC	Microsatellite Instability (MSI)/ Immunohistochemistry (IHC) Profile-Lynch/	☐ HPVLR	DNA In Situ F	lomavirus (HPV), Low-Risk, Hybridization		FISH, Tissue
	Hereditary Nonpolyposis Colorectal Cancer (HNPCC) Screen	☐ MAMLF	Mucoepiderm	21) Rearrangement, oid Carcinoma (MEC), FISH,	□ METF	MET (7q31), FISH, Tissue
□ IHC	Mismatch Repair (MMR) Protein Immunohistochemistry Only, Tumor	□ SGTF	Tissue MYB (6g23) R	learrangement, FISH, Tissue	ONCOLOGY Gastrointe	/: MOLECULAR DIAGNOSTIC TESTING
□ MSI	Microsatellite Instability (MSI), Tumor	Melanoma		, , , , , , ,	□ APCZ	APC Gene, Full Gene Analysis
□ RASFP	RAS/RAF Targeted Gene Panel by Next-	□ BRAFB		A BRAF V600 Test, Blood	☐ HCRC	Hereditary Colon Cancer Multi-Gene Panel
	Generation Sequencing, Tumor	□ BRAFC		on Analysis (V600), Melanoma	□ MSIHC	Microsatellite Instability (MSI)/
Genitourinary		☐ KIT11		Mutation Analysis		Immunohistochemistry (IHC) Profile-Lynch/
☐ TFE3F	Alveolar Soft Part Sarcoma (ASPS)/Renal	☐ KIT13	·	Mutation Analysis		Hereditary Nonpolyposis Colorectal Cancer (HNPCC) Screen
	Cell Carcinoma (RCC), Xp11.23 (TFE3), FISH, Tissue	☐ KIT17	•	Mutation Analysis	☐ LYNCH	Lynch Syndrome Panel
□ СТСРС	Circulating Tumor Cells (CTC) for Prostate	☐ MELF	Melanoma, Fl	SH, Tissue	☐ MLH1Z	MLH1 Gene, Full Gene Analysis
	Cancer by CellSearch, Blood	□ MELP		rgeted Gene Panel by Next-	□ MSH2Z	MSH2 Gene, Full Gene Analysis
☐ GCTF	Germ Cell Tumor (GCT), Isochromosome			equencing, Tumor	□ MSH6Z	MSH6 Gene, Full Gene Analysis
☐ H2URF	12p, FISH, Tissue HER2 Amplification Associated with	☐ UMM3F	Uveal Melano FISH, Tissue	ma, Chromosome 3 Monosomy,	□ MYHZ	MUTYH Analysis, Full Gene Analysis
	Urothelial Carcinoma, FISH, Tissue		·		-	

Patient Information (required)

Patient ID (Medical Record No.)	Client Account No.
Patient Name (Last, First, Middle)	Client Order No.
Birth Date (Month DD, YYYY)	

Gastrointe	estinal (cont.)
□ PMS2Z	PMS2 Gene, Full Gene Analysis
□ U1A1V	UDP-Glucuronosyl Transferase 1A1 TA Repeat
	Genotype, UGT1A1
□ UGTFG	UDP-Glucuronosyl Transferase 1A1 (UGT1A1),
	Full Gene Sequencing
Inherited I	Endocrine
☐ FMTT	Familial Mutation, Targeted Testing
☐ RETZ	RET Proto-Oncogene, Full Gene Analysis
☐ SDHP	SDHB, SDHC, SDHD Gene Panel
□ VHLZ	VHL Gene, Full Gene Analysis
PRIMARY	BODY FLUID TESTS
	sease monitoring or aiding in the diagnosis
Bone and	Soft Tissue
□ FGF23	Fibroblast Growth Factor 23 (FGF23), Plasma
Breast	
□ C2729	Breast Carcinoma-Associated Antigen (CA
	27.29), Serum
☐ CA153	Cancer Antigen 15-3 (CA 15-3), Serum
Endocrine	
Thyroid Car	icer
□ CATLN	Calcitonin, Fine-Needle Aspiration Biopsy (FNAB)-Needle Wash, Lymph Node
☐ CATN	Calcitonin, Serum
□ CEA	Carcinoembryonic Antigen (CEA), Serum
☐ TGMS	Thyroglobulin Mass Spectrometry, Serum
☐ HTGFN	Thyroglobulin, Tumor Marker, Fine-Needle Aspiration (FNA)-Needle Wash, Lymph Node
□ HTGR	Thyroglobulin, Tumor Marker Reflex to LC-MS/MS or Immunoassay
☐ HTG2	Thyroglobulin, Tumor Marker, Serum
Neuroendo	crine Tumors
□ CGAK	Chromogranin A, Serum
☐ GAST	Gastrin, Serum
□ GLP	Glucagon, Plasma
□ NSE	Neuron-Specific Enolase (NSE), Serum
☐ HPP	Pancreatic Polypeptide, Plasma
□ VIP	Vasoactive Intestinal Polypeptide (VIP), Plasma
Pituitary Tu	mors
□ ACTH	Adrenocorticotropic Hormone (ACTH), Plasma
□ APGH	Alpha-Subunit Pituitary Tumor Marker, Serum
□ FSH	Follicle-Stimulating Hormone (FSH), Serum
□ HGH	Growth Hormone, Serum
	Luteinizing Hormone (LH), Serum
□ MCRPL	Macroprolactin, Serum
□ NSE	Neuron-Specific Enolase (NSE), Serum
	D 1 11 Pil 11 M

☐ PLPMA Prolactin, Pituitary Macroadenoma, Serum

Prolactin, Serum

□ PRL

Biogenic A	mines
□ CATU	Catecholamine Fractionation, Free, 24 Hour, Urine
\square CATP	Catecholamine Fractionation, Free, Plasma
☐ HVA	Homovanillic Acid (HVA), 24 Hour, Urine
☐ HVAR	Homovanillic Acid (HVA), Random, Urine
□ HIAA	5-Hydroxyindoleacetic Acid (5-HIAA), 24 Hour, Urine
☐ METAF	Metanephrines, Fractionated, 24 Hour, Urine
☐ PMET	Metanephrines, Fractionated, Free, Plasma
☐ METAR	Metanephrines, Fractionated, Random, Urine
☐ SERU	Serotonin, 24 Hour, Urine
☐ SERWB	Serotonin, Blood
□ VH	VanillyImandelic Acid (VMA) and Homovanilli Acid (HVA), Random, Urine
□ VMA	VanillyImandelic Acid (VMA), 24 Hour, Urine
□ VMAR	Vanillylmandelic Acid (VMA), Random, Urine
Gastrointe	estinal
☐ L3AFP	Alpha-Fetoprotein (AFP) L3% and Total,
	Hepatocellular Carcinoma Tumor Marker, Serum
☐ AFPPT	Alpha-Fetoprotein (AFP), Peritoneal Fluid
☐ AFP	Alpha-Fetoprotein (AFP) Tumor Marker, Serum
☐ AMLPC	Amylase, Pancreatic Cyst
□ 199PC	Carbohydrate Antigen 19-9 (CA 19-9), Pancreatic Cyst Fluid
□ 199PT	Carbohydrate Antigen 19-9 (CA 19-9), Peritoneal Fluid
☐ CA19	Carbohydrate Antigen 19-9 (CA 19-9), Serur
☐ CEAPC	Carcinoembryonic Antigen (CEA), Pancreatic Cyst Fluid
□ CEAPT	Carcinoembryonic Antigen (CEA), Peritoneal Fluid
□ CEA	Carcinoembryonic Antigen (CEA), Serum
□ CGAK	Chromogranin A, Serum
□ DCP	Des-Gamma-Carboxy Prothrombin (DCP), Serum
□ F0BT	Fecal Occult Blood, Colorectal Cancer Screen, Qualitative, Immunochemical
☐ GAST	Gastrin, Serum
□ GLP	Glucagon, Plasma
□ HIAA	5-Hydroxyindoleacetic Acid (5-HIAA), 24 Hour, Urine
\square NSE	Neuron-Specific Enolase (NSE), Serum
☐ HPP	Pancreatic Polypeptide, Plasma
☐ SERU	Serotonin, 24 Hour, Urine
□ SERWB	Serotonin, Blood
□ VIP	Vasoactive Intestinal Polypeptide (VIP), Plasma

Genitourin	nary
☐ AFPSF	Alpha-Fetoprotein (AFP), Spinal Fluid
☐ AFP	Alpha-Fetoprotein (AFP) Tumor Marker, Serum
□ BHCG	Beta-Human Chorionic Gonadotropin, Quantitative, Serum
□ BHSF	Beta-Human Chorionic Gonadotropin, Quantitative, Spinal Fluid
☐ CEASF	Carcinoembryonic Antigen (CEA), Spinal Fluid
□ PSA	Prostate-Specific Antigen (PSA) Diagnostic, Serum
□ SPSA	Prostate-Specific Antigen (PSA) Screen, Serum
☐ PHI11	Prostate Health Index (phi), Serum
□ PSAFT	Prostate-Specific Antigen (PSA), Total and Free, Serum
Gynecolog	ıy
□ BHCG	Beta-Human Chorionic Gonadotropin, Quantitative, Serum
□ CA25	Cancer Antigen 125 (CA 125), Serum
☐ HE4	Human Epididymis Protein 4, Serum
□ INHA	Inhibin A, Tumor Marker, Serum
□ INHAB	Inhibin A and B, Tumor Marker, Serum
□ INHB	Inhibin B, Serum
□ ROMA	Ovarian Malignancy Risk Algorithm
Pulmonar	у
□ PF199	Carbohydrate Antigen 19-9 (CA 19-9), Pleura Fluid
□ PFCEA	Carcinoembryonic Antigen (CEA), Pleural Fluid
□ NSE	Neuron-Specific Enolase (NSE), Serum

ADDITIONAL TESTS (INDICATE TEST CODE AND NAME)